- Tensions reach boiling point over codeine changes
- We all have to die of something, so why bother being healthy?
- Male neurosurgeons highest ATO earners, GPs in top 50
- What are we training medical students for?
- Hypertension linked to valve disorder
- Victoria’s assisted dying legislation: how it would work
- Australia deepens its ties to World Health Organisation
- New GP guide for prescribing benzodiazepines to help prevent ‘doctor shopping’
Advances and developments in infectious diseases for primary care – Sydney
Hepatitis C is a significant public health problem and one of the most common notifiable diseases in Australia. Of those exposed to the virus, 75 per cent go on to develop a chronic hepatitis C infection. The risk of progressive hepatitis C-related liver disease increases with the duration of chronic infection. At the end of 2012, there were an estimated 230 000 people living with chronic hepatitis C infection in Australia.
Antimicrobial resistance remains a global challenge. It results in about 2000 attributable deaths per year in Australia and a projected 10 million globally by 2050. As antibiotics become less effective, old diseases re-emerge, many in Australia’s near neighbours.
A lack of clarity surrounds prescribing guidelines for new-generation hepatitis C drugs. A key aspect of the guidelines is that general practitioners will need to establish whether or not a patient has cirrhosis, but exactly what will satisfy a specialist is still uncertain.
Herpes zoster, or shingles, can occur at virtually any age but is most common after the age of 50 years, and carries a lifetime risk of up to 50% in people living for 85 years or more. Vaccines have been shown to be both safe and efficacious However, there are several important unanswered questions, including the duration of efficacy, safety in mildly immunocompromised patients and use in younger patients.
There were 21,812 notifiable diseases reported in Australia in April this year. Diseases with the highest incidence include Hepatitis C, chlamydia, herpes zoster virus, influenza and gastrointestinal diseases.
Join us for an active learning module which will address challenging issues in diagnosis and management in the general clinical setting. This module is accredited for RACGP QI&CPD 40 Category 1 points and 30 ACRRM PDP points. Other colleges are able to self-report the 6 hours of structured learning with the Certificate of Attendance issued after the Seminar.
WHEN: Saturday 17 September 2016 from 9am – 5pm
WHERE: Sydney – Four Points by Sheraton
PROGRAM: CLICK HERE to download the latest program.
COST: Registration cannot be completed successfully without full payment. An incomplete registration without full payment authorisation does not constitute a registration and will be rejected by doctorportal.
|AMA Members – flat rate||$316|
|Early Bird Registration
(register before 12 August 2016)
(register after 12 August 2016)
To REGISTER for this event, follow the registration process below:
To submit a registration form by fax/email, download the registration form here.